# A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

> **NCT05623020** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 1116 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT05623020
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-10
- **Primary completion:** 2030-10-18
- **Final completion:** 2033-10-03
- **Target enrollment:** 1116 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623020, "A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05623020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*